Suchergebnisse - "Schmid, Peter"

PubPharm (15)

1

Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer : exploratory analysis from KEYNOTE-119

enthalten in: The journal of pathology. Clinical research | 2024

von Cortes, J. | Winer, E. | Lipatov, O. | +18

2

Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer : results from the phase 3 randomised KEYNOTE-119 study

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von Schmid, P. | Lipatov, O. | Im, S. | +18

3

Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer : A Secondary Analysis of a Randomized Clinical Trial

enthalten in: JAMA network open | 2023

von Takahashi, M. | Cortés, J. | Dent, R. | +17

4

Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer : KEYNOTE-086 Exploratory Analysis

enthalten in: JCO precision oncology | 2023

von Loi, S. | Salgado, R. | Schmid, P. | +20

5

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

enthalten in: The New England journal of medicine | 2022

von Cortes, J. | Rugo, H. | Cescon, D. | +117

CommentIn: N Engl J Med. 2022 Jul 21;387(3):273-274. - PMID 35857664

6

PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer

enthalten in: Journal of the National Cancer Institute | 2021

von Rugo, H. | Loi, S. | Adams, S. | +14

CommentIn: J Natl Cancer Inst. 2021 Nov 29;113(12):1613-1614. - PMID 34097056

7

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer : Biomarker Evaluation of the IMpassion130 Study

enthalten in: Journal of the National Cancer Institute | 2021

von Emens, L. | Molinero, L. | Loi, S. | +12

8

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119) : a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Winer, E. | Lipatov, O. | Im, S. | +18

CommentIn: Lancet Oncol. 2021 Jun;22(6):e224. - PMID 34087134

9

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355) : a randomised, placebo-controlled, double-blind, phase 3 clinical trial

enthalten in: Lancet (London, England) | 2020

von Cortes, J. | Cescon, D. | Rugo, H. | +118

CommentIn: Lancet. 2021 Jul 3;398(10294):24. - PMID 34217392

10

IMpassion132 Phase III trial : atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer

enthalten in: Future oncology (London, England) | 2019

von Cortés, J. | André, F. | Gonçalves, A. | +9